Document Detail

Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
MedLine Citation:
PMID:  22057076     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Osteoporosis develops and progresses in a considerable number of kidney transplant patients. Bisphosphonates, which are used for prevention and treatment of osteoporosis, may accentuate gasterointestinal complications and lead to more nonadherence to treatment. This randomized clinical trial was conducted to compare the effect of pamidronate versus alendronate on early bone mineral density changes in kidney transplant patients.
MATERIALS AND METHODS: Forty patients (27 men and 13 women), aged from 20 to 58 years, with low bone mineral density (T score < -2) in the spine, total hip, or femur neck were enrolled. Participants were randomly allocated into 2 groups to receive pamidronate or alendronate. The pamidronate group received intravenous pamidronate, 90 mg, starting from the 3rd week of transplantation for 3 months. The alendronate group started to receive oral alendronate, 70 mg per week for the same period. At baseline and 6 months, bone mineral density was measured by dual-energy x-ray absorptiometry. Gastrointestinal side effects were monitored every month.
RESULTS: No significant difference was found in bone density changes of the lumber area between the two groups; however, significantly less reduction in bone mineral density of the femur neck and femur occurred in the pamidronate group. Kidney function and parathyroid hormone levels were similar in the two groups before and after the study. Gastrointestinal side effects were seen in 3 patients of the alendronate group only.
CONCLUSIONS: Pamidronate was comparable to alendronate in prevention of early bone loss after kidney transplantation.
Bita Omidvar; Ali Ghorbani; Heshmatollah Shahbazian; Seyed Seifollah Beladi Mousavi; Seyed Javad Shariat Nabavi; Mohammad Alasti
Related Documents :
21909046 - Lethal pulmonary complications after pediatric allogeneic hematopoietic stem cell trans...
21874436 - Successful treatment of bronchial anastomotic stenosis with modified dumon y-stent inse...
5031656 - Pharmacodynamics of propranolol in renal failure.
22078456 - Developing treatment options for metachromatic leukodystrophy.
17240706 - Sudden sensorineural hearing loss and hemodialysis.
19034226 - Quality of life after liver transplantation--preliminary report.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Iranian journal of kidney diseases     Volume:  5     ISSN:  1735-8604     ISO Abbreviation:  Iran J Kidney Dis     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-07     Completed Date:  2012-03-13     Revised Date:  2012-09-13    
Medline Journal Info:
Nlm Unique ID:  101316967     Medline TA:  Iran J Kidney Dis     Country:  Iran    
Other Details:
Languages:  eng     Pagination:  420-4     Citation Subset:  IM    
Department of Nephrology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Absorptiometry, Photon
Administration, Oral
Alendronate / administration & dosage*
Anti-Inflammatory Agents
Bone Density
Bone Density Conservation Agents / administration & dosage*
Bone Diseases, Metabolic / drug therapy*,  metabolism,  radiography
Diphosphonates / administration & dosage*
Dose-Response Relationship, Drug
Follow-Up Studies
Injections, Intravenous
Kidney Diseases / surgery
Kidney Transplantation*
Middle Aged
Time Factors
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Bone Density Conservation Agents; 0/Diphosphonates; 40391-99-9/pamidronate; 66376-36-1/Alendronate
Erratum In:
Iran J Kidney Dis. 2012 Jul;6(4):321

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Urinary tract infection after kidney transplantation in children and adolescents.
Next Document:  A 22-year-old woman with hypertension and hypokalemia due to a juxtaglomerular cell tumor.